Kopran Ltd’s record carries three things that deserve attention: promoter control has tightened to 55% through board appointments and a scheme of arrangement that public institutions voted 97% against, trade receivables have doubled to ₹262.66 crore with 141 days outstanding, and cumulative operating cash flow covers only 53% of EBITDA over the last decade.
Key findings
- Promoter control tightens to 55% as public institutions vote 97% against the Chairman’s reappointment
Major- Promoter shareholding rose from 44.46% to 55.36% under a Scheme of Arrangement approved on March 20, 2025. At the September 11, 2025 AGM, public institutional shareholders voted 96.85% against appointing Mr. Surendra Somani as Chairman & Managing Director, while the promoter group voted 100% in favour with 10,775,628 votes. Mrs. Namrata Somani, daughter-in-law of Mr. Surendra Somani, was appointed Additional Director on May 19, 2026. - One customer is 17% of product revenue, and trade receivables stretch to 141 days
Major- Consolidated trade receivables grew from ₹127.36 crore in FY22 to ₹262.66 crore in FY26, with the credit period stated at 90 to 180 days across all years. One customer accounted for ₹52.05 crore or 17.15% of standalone revenue from operations from sale of products in FY26. The FY23 auditor’s report flagged allowance for trade receivables as a Key Audit Matter, citing significant judgment on recoverability of overdue balances. - Disputed tax and DPCO demands exceed 6 crore, with PF contribution exposure still unquantified
Minor- Disputed income tax demands stood at 2.08 crore and service tax demands at 5.08 crore as of March 31, 2023, both unchanged from the prior year. A DPCO-95 demand of 5.91 crore remains pending in appeal before the High Court Mumbai. The company has not quantified potential PF contribution liability following the February 2019 Supreme Court ruling. - Operating cash flow covers profit each year, but cumulative conversion is weak
Minor- FY26 operating cash flow of ₹66.75 crore covered profit after tax of ₹25.73 crore by 2.59 times, while FY22 cash flow was negative ₹33.48 crore against profit of ₹61.03 crore. Cumulative CFO of ₹310 crore covered only 53% of cumulative EBITDA of ₹590 crore over the ten-year window through FY26. ROCE declined from 12.89% in FY24 to 6.56% in FY26.
What to watch
- Scheme of Amalgamation. Kopran Laboratories Ltd. is to merge into Kopran Ltd., pending final NCLT sanction after shareholder and creditor approvals obtained per the NCLT order dated April 09, 2026.
- SEBI disclosure requirement. Details of any ongoing adjudication, recovery, prosecution, or enforcement action against the company, promoters, and directors must be disclosed before NCLT and shareholders, as required by SEBI’s February 26, 2026 letter.
- DPCO-95 demand. The 5.91 crore disputed in appeal before the High Court Mumbai as of the FY2022-23 reporting period awaits resolution.
- PF contribution exposure. The company has yet to quantify liability following the February 2019 Supreme Court judgment as of the FY2022-23 reporting period.
Bottom line: This is a disclosed and audited record. The risk sits in two places: governance, where promoter control has tightened to 55% against near-unanimous institutional opposition, and credit, where receivables stretch to 141 days with a single customer at 17% of sales. Watch the scheme completions and the SEBI disclosure requirement, and read the receivables line with concentration risk in mind.